Geron Corporation

GERN Healthcare Biotechnology

Geron Corporation’s revenue for fiscal 2025 (year ended December 2025) was $183.9 million, up 138.8% from fiscal 2024. In the quarter to June 2026, revenue grew 17.2%, EPS was flat, free cash flow grew 41.8% and total debt was flat, each against the same quarter a year earlier.

1.17 0.06 −4.88%
Market cap
$790.2M
P/E
0.0×
Fwd P/E
−58.5×
Dividend yield
—
F-score
3/9
Altman Z
−2.24
Beneish M
−1.70
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
4.98 4.79 5.09 4.20
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(67.32) (39.88) (15.85) (54.24)
P/B ratio
3.67 3.90 4.35 3.93
EV/Sales
3.94 3.87 4.46 3.65
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(5.44) (6.40) (6.92) (6.51)
Current Ratio
5.96 4.66 6.78 6.92
Net Debt/EBITDA
17.74 9.09 650.34 14.52
Debt/Equity
0.48 0.53 0.52 0.55
Earnings Yield
(8.76%) (9.85%) (7.07%) (8.23%)
Free Cash Flow Yield
(14.53%) (12.62%) (12.66%) (13.37%)
Free Cash Flow per Share
(0.02) (0.03) (0.09) (0.02)
Book value per Share
0.37 0.34 0.34 0.33
Free Cash Flow
(13.49) (22.07) (63.16) (16.05)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates